Largest biotech companies by cash on hand
Cash and cash equivalents at the end of the latest fiscal year. Short-term investments are not counted.
Amgen leads the 24 biotech companies ranked by cash on hand, at DKK 62.1B, ahead of BioNTech (DKK 58B) and Gilead Sciences (DKK 51.5B). Figures as of 18 Nov 2026, 22:17 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 24
- First
- AmgenDKK 62.1B
- Median
- DKK 2.9B
- Combined market value
- DKK 5.69T
- Countries
- 5
Market values as of .
All countries▾
All sectors▾
Biotech▾
| # | Company | Cash on hand ↓ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | AmgenAMGN · Health Care | DKK 62.1B | DKK 1.63T | DKK 3,021.98 | 3.07% down | 34% up | ||
| 2 | BioNTechBNTX · Health Care | DKK 58B | DKK 140.5B | DKK 566.83 | 1.89% down | 16% down | ||
| 3 | Gilead SciencesGILD · Health Care | DKK 51.5B | DKK 1.43T | DKK 1,150.41 | 0.75% down | 33% up | ||
| 4 | argenxARGX · Health Care | DKK 23.8B | DKK 403B | DKK 6,407.98 | 0.66% down | 4% up | ||
| 5 | BiogenBIIB · Health Care | DKK 20.5B | DKK 253B | DKK 1,711.59 | 0.25% up | 49% up | ||
| 6 | ModernaMRNA · Health Care | DKK 17.7B | DKK 542.1B | DKK 1,339.74 | 4.84% down | 755% up | ||
| 7 | ImmunovantIMVT · Health Care | DKK 6.1B | DKK 46.7B | DKK 225.82 | 0.12% down | 43% up | ||
| 8 | QiagenQGEN · Health Care | DKK 5.7B | DKK 69.7B | DKK 337.40 | 0.38% down | 12% up | ||
| 9 | Neurocrine BiosciencesNBIX · Health Care | DKK 4.9B | DKK 112.2B | DKK 1,108.74 | 1.84% down | 20% up | ||
| 10 | RepligenRGEN · Health Care | DKK 3.9B | DKK 75.1B | DKK 1,175.53 | 6.47% up | 5% up | ||
| 11 | Krystal BiotechKRYS · Health Care | DKK 3.4B | DKK 63.6B | DKK 2,146.82 | 5.62% up | 46% up | ||
| 12 | ExelixisEXEL · Health Care | DKK 3.3B | DKK 113.4B | DKK 464.91 | 0.31% down | 63% up | ||
| 13 | Revolution MedicinesRVMD · Health Care | DKK 2.6B | DKK 235.3B | DKK 1,088.05 | 1.76% down | 131% up | ||
| 14 | Kymera TherapeuticsKYMR · Health Care | DKK 2.4B | DKK 70.4B | DKK 824.65 | 0.32% down | 87% up | ||
| 15 | CRISPR TherapeuticsCRSP · Health Care | DKK 2.4B | DKK 26.5B | DKK 273.61 | 0.10% up | 21% down | ||
| 16 | Scholar Rock HoldingSRRK · Health Care | DKK 2.2B | DKK 39.9B | DKK 326.78 | 6.48% up | 14% up | ||
| 17 | Bio-TechneTECH · Health Care | DKK 1.8B | DKK 77.8B | DKK 495.28 | 0.17% up | 26% up | ||
| 18 | Kodiak SciencesKOD · Health Care | DKK 1.4B | DKK 43.5B | DKK 665.89 | 1.04% up | 396% up | ||
| 19 | Twist BioscienceTWST · Health Care | DKK 1.2B | DKK 54B | DKK 792.10 | 3.88% up | 340% up | ||
| 20 | VaxcytePCVX · Health Care | DKK 1.2B | DKK 63.1B | DKK 398.40 | 1.48% down | 22% up | ||
| 21 | Halozyme TherapeuticsHALO · Health Care | DKK 911M | DKK 74.4B | DKK 652.20 | 0.18% down | 37% up | ||
| 22 | ImmunityBioIBRX · Health Care | DKK 601.4M | DKK 48.5B | DKK 45.61 | 7.03% up | 193% up | ||
| 23 | Adaptive BiotechnologiesADPT · Health Care | DKK 479.9M | DKK 31.4B | DKK 193.75 | 0.11% down | 88% up | ||
| 24 | CG OncologyCGON · Health Care | DKK 221.2M | DKK 48.6B | DKK 544.64 | 1.34% up | 85% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration; annual figures from the reports companies file with the SEC.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Cash on hand is from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day, not of the period. Sums are converted from US dollars at today's exchange rate (1 USD = 6.8079 DKK).
Questions and answers
Which biotech companies rank first by cash on hand?
Amgen (DKK 62.1B), BioNTech (DKK 58B) and Gilead Sciences (DKK 51.5B) are the top three of the 24 biotech companies ranked by cash on hand as of 18 Nov 2026, 22:17 UTC.
How many biotech companies are in this ranking?
24 are ranked by cash on hand.
What are these biotech companies worth together?
The 24 biotech companies ranked by cash on hand have a combined market value of DKK 5.69T as of 18 Nov 2026, 22:17 UTC.
What does ranking by cash on hand measure?
Cash and cash equivalents at the end of the latest fiscal year. Short-term investments are not counted.
Learn how this ranking works
All markets guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Largest biotech companies by cash on hand”, data as of 18 November 2026. https://funkfolio.com/companies/category/biotech?by=cash-on-hand
Underlying data: Yahoo Finance; SEC EDGAR.